Diffusion Tensor Imaging (DTI)
DTI is rapidly becoming an established technique that non-invasively maps microscopic structural information of oriented tissue in vivo. DTI is a magnetic resonance imaging technique that allows for the visualization and characterization of the white matter tracts of the brain in vivo.The growing number of DTI-based studies, applied and methodological, shows the great potential of this method.
Fig.1 Typical DTI workflow. (Soares, 2013)
How is DTI Analyzed?
- Measures
The data from the tensor model at the level of each voxel and subsequently in a region can be summarized and visualized in three different ways: mean diffusivity, degree of anisotropy, and the main direction of diffusivity. The final measure that can be extracted from the tensor is based on the orientation in space of the tissue structure. DTI is better suited for analyzing large fiber bundles than small tracts.
Fig.2 Quantitative maps from a DTI experiment. (Alexander, 2007)
- Analytic Strategies
- Whole brain analysis or voxel-based morphometry
- Tract-based spatial statistics
- Region of interest (ROI) analysis
- Fiber tract reconstruction or tractography
Multiple analytic strategies provide spatial localization for the measures from DTI. Here summarize 4 strategies.
Voxel-based morphometry implies that the images have been aligned using a protocol called spatial normalization. Spatial normalization uses computer-based algorithms to turn, stretch, shrink, and warp each brain image to make the best fit possible to a template. The next step in voxel-based morphometry is the analysis of voxels that meet a threshold value of FA, such as 0.20, to avoid including areas of gray matter or cerebral spinal fluid.
Tract-based spatial statistics roughly aligns the FA images from multiple subjects to a common space using an algorithm. It then creates a tract representation, called the “mean FA skeleton” including only those voxels assumed to be at the center of tracts common to all the members of the group and excluding regions of poor alignment.
This method relies on a priori spatial definitions of brain structures and analyzes only those voxels within the region. In the ROI approach, the number of statistical comparisons is considerably lower than in a whole brain approach. The advantages are therefore that statistical power increases and small differences not apparent on whole brain analyses may be found. A major disadvantage of this method is that it may miss differences in regions not included in the analysis.
Fiber tract reconstruction, or diffusion tensor tractography, is a method used to identify and visualize a continuous 3-dimensional trajectory by sequentially piecing together the estimates of fiber orientation from the directionality of individual voxels.
Fig.3 DTI tractography. (Wilkinson, 2016)
Clinical Applications of DTI in Neuropsychiatric Disorders
- Traumatic Brain Injury
- Brain Tumors
- Seizure Disorders
- Other Conditions Affecting White Matter
- Alzheimer's Disease
DTI allows a closer investigation of the specific fiber tracts affected, as well as the ability to monitor the degeneration process following injury. The case studies suggest that DTI is a powerful new technology for investigating functional deficits caused by brain injury, as well as for predicting prognosis.
DTI can be implemented for tumor modeling fiber-tract disruptions or displacement caused by the and could be useful for early detection of spine metastases, as well as for detection of corticospinal-tract disruptions or displacement.
A few existing DTI studies already demonstrate higher sensitivity of DTI compared to structural MRI in detecting malformations of cortical development. Such malformations disturb the orientation of the fiber tracts and are a common cause of epilepsy.
DTI studies in patients with MS have shown an increase in mean diffusivity and a decrease in diffusion anisotropy within acute lesions, as well as within the normal-appearing white matter, most likely attributable to edema. In addition, DTI is useful in differentiating between two types of MS, secondary progressive and relapsing-remitting, which have different clinical courses.
DTI studies may improve our ability to track progressive changes in Alzheimer's disease and could be used in the future to evaluate changes in response to treatment.
DTI is a powerful method for characterizing changes in tissue microstructure associated with brain disorders. Creative Biolabs has a very strong technical force in the field of neuroscience research, focusing on DTI research in recent years. We can develop customized DTI solutions for customer’s neuroscience research projects to make the greatest breakthrough in your project. Contact us for more information.
References
- Soares, J.M.; et al. A hitchhiker's guide to diffusion tensor imaging. Front Neurosci. 2013 Mar 12; 7: 31.
- Alexander, A.L.; et al. Diffusion tensor imaging of the brain. Neurotherapeutics. 2007 Jul; 4(3): 316-29.
- Wilkinson, M.; et al. White and gray matter fiber pathways in autism spectrum disorder revealed by ex vivo diffusion MR tractography. Brain Behav. 2016, 6: e00483.
- NeuroMab™ Anti-CD20 Antibody(NRP-0422-P1230) (Cat#: NRP-0422-P1230)
- NeuroMab™ Anti-TREM2 BBB Shuttle Antibody(NRZP-1022-ZP4114) (Cat#: NRZP-1022-ZP4114)
- NeuroMab™ Anti-Amyloid Beta 1-15 Antibody(NRP-0422-P867) (Cat#: NRP-0422-P867)
- NeuroMab™ Anti-TREM2 Antibody(NRP-0422-P792) (Cat#: NRP-0422-P792)
- NeuroMab™ Anti-GARP Antibody(NRP-0422-P1639) (Cat#: NRP-0422-P1639)
- NeuroMab™ Anti-Tau Antibody(NRP-0422-P1686) (Cat#: NRP-0422-P1686)
- NeuroMab™ Anti-Tau Antibody(NRP-0422-P1684) (Cat#: NRP-0422-P1684)
- NeuroMab™ Anti-ApoC3 BBB Shuttle Antibody(NRZP-1022-ZP3505) (Cat#: NRZP-1022-ZP3505)
- NeuroMab™ Anti-Alpha Synuclein BBB Shuttle Antibody(NRZP-1022-ZP4050) (Cat#: NRZP-1022-ZP4050)
- NeuroMab™ Anti-GD2 Antibody(NRZP-1222-ZP767) (Cat#: NRZP-1222-ZP767)
- Immortalized Human Cerebral Microvascular Endothelial Cells (Cat#: NCL-2108-P020)
- Human Brain Astroblastoma U-87 MG (Cat#: NCL2110P117)
- Mouse Midbrain Dopaminergic Neuron Cell MN9D (Cat#: NCL2110P059)
- Green Fluorescent Alpha-synuclein SH-SY5Y Cell Line (Cat#: NCL2110P209)
- Rat Olfactory Ensheathing Cells (Cat#: NRZP-1122-ZP162)
- Rat Immortalized Retinal Muller Cell Line rMC-1 (Cat#: NCL-2106-S93)
- Human Neurons Isolated from Cortex (Cat#: NCL-21P6-023)
- Human Brain Microvascular Endothelial Cells (Cat#: NCL-2103-P133)
- Mouse Glioma Cell Line GL261-GFP (Cat#: NCL-2108P04)
- Green Fluorescent Tau SH-SY5Y cell Line (Cat#: NCL2110P219)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Dextran, NHS Activated, 40 kDa (Cat#: NRZP-0722-ZP124)
- AAV-mDLX-CRE-tdTomato (Cat#: NRZP-0622-ZP721)
- VSV-eGFP (Cat#: NTA-2011-ZP20)
- AAV-EF1a-mCherry-flex-dtA (Cat#: NRZP-0622-ZP616)
- AAV2 Full Capsids, Reference Standards (Cat#: NTC2101070CR)
- rAAV-CAG-DIO-G-Flamp1 (Cat#: NRZP-0722-ZP719)
- Dextran, Cy5 Labeled, 2000 kDa (Cat#: NRZP-0722-ZP22)
- Dextran-FITC (Cat#: NTA-2011-ZP110)
- AAV2/2Retro-CAG-DIO-EGFP-2A-TetTox-pA [Neural Tracing] (Cat#: NTA-2012-ZP303)
- AAV2/9-hSyn-Flpo-EGFP-WPRE-pA (Cat#: NTA-2012-ZP149)
- Human apolipoprotein E (APOE) (NM_000041) ORF clone, Untagged (Cat#: NEP-0421-R0232)
- Tau Antisense Oligonucleotide (IONIS-MAPTRx) (Cat#: NV-2106-P29)
- Human presenilin 1 (PSEN1), transcript variant 2 (NM_007318) ORF clone, TurboGFP Tagged (Cat#: NEP-0421-R0140)
- ABCA1 Antisense Oligonucleotide (NV-2106-P27) (Cat#: NV-2106-P27)
- Human huntingtin (HTT) (NM_002111) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0497)
- Mouse Parkinson disease (autosomal recessive, early onset) 7 (Park7) (NM_020569) clone, Untagged (Cat#: NEP-0621-R0133)
- Lenti of Mouse synuclein, alpha (Snca) transcript variant (NM_001042451) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0864)
- Human superoxide dismutase 1, soluble (SOD1) (NM_000454) ORF clone, TurboGFP Tagged (Cat#: NEP-0521-R0748)
- Mouse SOD1 shRNA Silencing Adenovirus (Cat#: NV-2106-P14)
- Lenti of Human TAR DNA binding protein (TARDBP) (NM_007375) ORF clone, mGFP Tagged (Cat#: NEP-0521-R0832)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroPro™ Anti-SGSH BBB Shuttle Protein (Cat#: NRZP-0423-ZP505)
- NeuroPro™ Anti-idursulfase BBB Shuttle Protein (Cat#: NRZP-0423-ZP497)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP501)
- NeuroPro™ Anti-PON1 BBB Shuttle Protein (Cat#: NRZP-0423-ZP507)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP509)
- NeuroPro™ Anti-EPO BBB Shuttle Protein (Cat#: NRZP-0423-ZP508)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP502)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP498)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP500)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP510)